



Investor News

Bayer CropScience announces supply agreement for Imidacloprid with Cheminova

Monheim (Germany) / 19. April 2005 – Bayer CropScience has agreed to supply Cheminova with its Imidacloprid insecticide as part of a multi-year, non-exclusive supply contract for agricultural and non-agricultural applications (excluding Animal Health uses). The agreement has been signed as of April 18, 2005. The terms of the agreement are confidential.

The active ingredient Imidacloprid was discovered by Bayer CropScience and is today one of the most successful in the world. Through the supply agreement, Bayer CropScience and Cheminova aim at further expanding the market for Imidacloprid-based applications by drawing on the strength of their respective distribution channels.

Imidacloprid belongs to the chloronicotinyl class of substances and protects more than 140 crops against many sucking insects. Bayer CropScience will continue to actively market its Imidacloprid-based product line in more than 100 countries. Cheminova will develop and commercialize their own range of products based on Imidacloprid, beginning in some countries and markets in 2005.

“The supply contract with Cheminova is another important step as part of our life cycle management strategy for Imidacloprid and we are pleased to have reached this agreement. Bayer CropScience is the only company able to draw on three chloronicotinyl compounds in its portfolio, and we plan to continue to strongly grow our business in this category. As the market and innovation leader in the insecticides segment, we have all intention to further expand our market position by launching new active ingredients and optimizing the commercial value of our existing portfolio”, said Dr. Rüdiger Scheitza, Member of the Board of Bayer CropScience.

“By signing this agreement covering the world’s best-selling insecticide, Cheminova has reached an important milestone in expanding its portfolio of insecticides.

Cheminova is today offering a wide range of organophosphate and pyrethroid based insecticides and by adding Imidacloprid, belonging to a new class of insecticides, the product portfolio of Cheminova will be strengthened significantly. Cheminova expects its Imidacloprid products to be sold in several markets already this year and within a few years to contribute significantly to Cheminovas turnover and profitability”, said Bjørn Albinus, Managing Director of Cheminova.

Bayer CropScience, a subsidiary of Bayer AG with annual sales of about EUR 6.0 billion, is one of the world’s leading innovative crop science companies in the areas of crop protection, non-agricultural pest control, seeds and plant biotechnology. The company offers an outstanding range of products and extensive service backup for modern, sustainable agriculture and for non-agricultural applications. Bayer CropScience has a global workforce of about 19,000 and is represented in more than 120 countries. Further information is also available at:
<http://www.bayercropscience.com>

Cheminova A/S, a subsidiary of the danish company Auriga Industries A/S, is a manufacturer of fine chemicals, with its main business area within plant protection products. Cheminova is offering a portfolio of generic and proprietary products, and is marketing its products globally through subsidiaries in 14 key countries and through distribution partners in most other countries. The annual turnover of Cheminova is EUR 550 Mio. The company employs 1500 people, 800 in Denmark and 700 abroad.

Monheim, April 19, 2005

Bayer AG, Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)

Dr. Juergen Beunink (+49-214-30-65742)

Peter Dahlhoff (+49-214-30-33022)

Ute Krippendorf (+49-214-30-33021)

Ilia Kürten (+49-214-30-35426)

Judith Nestmann (+49-214-30-66836)

Forward-looking statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer CropScience AG management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future consolidated results, financial situation, development or performance of the Bayer CropScience AG or our parent company, Bayer AG, and the estimates given here. These factors include those discussed in Bayer AG’s public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including Bayer AG’s Form 20-F). Neither Bayer AG nor Bayer CropScience AG assumes any liability whatsoever to update these forward-looking statements or to conform them to future events or developments.